Russian Journal of ImmunologyRussian Journal of Immunology1028-72212782-7291Russian Society of Immunology55110.31857/S102872210007057-7CLINICAL EXPERIENCE WITH IMMUNOGLOBULIN SIGARDIS AS REPLACEMENT THERAPY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCYDrobyshevskayaV. G.<p>аllergist-immunologist, Medical Center;</p><p>high school teacher, Department of Immunology,</p><p>St. Petersburg</p>v.g.drobyshevskaia@yandex.ruKrivtsunO. A.<p>student,</p><p>St. Petersburg</p>fake@neicon.ruSt. Petersburg Pasteur Research Institute of Epidemiology and MicrobiologyFirst St. Petersburg State I. Pavlov Medical University20122019224146014622010202020102020Copyright © 2019, Drobyshevskaya V.G., Krivtsun O.A.2019<p>Practically valuable information on the use of the IMMUNOGLOBULIN SIGARDIS drug as a pathogenetic treatment of patients with a defect in antibody production. The article presents data from the study of the drug for compliance with the criteria, presented to the Intravenous immunoglobulin by the World Health Organization, the comparative characteristics of the antibodies that make up the drug according to the spectra and titers with the Russian, the data on the clinical and laboratory efficacy of the drug. </p>“IMMUNOGLOBULIN SIGARDIS”Intravenous immunoglobulinprimary immunodeficiencyreplacement therapy of primary immunodeficiencythe efficacy of pathogenetic therapy of Immunodeficiencythe safety of pathogenetic therapy of Immunodeficiency«IMMUNOGLOBULIN SIGARDIS»ВВИГПИДзаместительная терапия первичных иммунодефицитовэффективность патогенетической терапии ПИДбезопасность патогенетической терапии ПИД[1. Латышева Е. А. «Первичные иммунодефициты у взрослых. Особенности диагностики и лечения.», Москва, 2018 г.][2. Федеральные клинические рекомендации по диагностике и лечению больных первичными иммунодефицитами с нарушением гуморального звена. РААКИ, Москва 2014 год.]